S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:TROVTrovaGene News Headlines

$5.97
-0.49 (-7.59 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.82
Now: $5.97
$6.57
50-Day Range
$3.19
MA: $4.77
$6.21
52-Week Range
$0.70
Now: $5.97
$3.46
Volume662,786 shs
Average Volume648,892 shs
Market Capitalization$65.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04

Headlines

TrovaGene (NASDAQ TROV) News Headlines

Source:
DateHeadline
TrovaGene Inc (NASDAQ:TROV) Short Interest Up 421.5% in JanuaryTrovaGene Inc (NASDAQ:TROV) Short Interest Up 421.5% in January
americanbankingnews.com - August 11 at 3:52 PM
TrovaGene (NASDAQ:TROV) Stock Price Crosses Above 200-Day Moving Average of $2.20TrovaGene (NASDAQ:TROV) Stock Price Crosses Above 200-Day Moving Average of $2.20
americanbankingnews.com - August 6 at 3:40 AM
Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference - PRNewswireCardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference - PRNewswire
prnewswire.com - August 4 at 9:43 AM
Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology ConferenceCardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference
finance.yahoo.com - August 4 at 9:43 AM
Cardiff Oncology to Participate in the William Blair Biotech Focus Conference - Yahoo FinanceCardiff Oncology to Participate in the William Blair Biotech Focus Conference - Yahoo Finance
finance.yahoo.com - July 30 at 3:11 PM
TrovaGene (NASDAQ:TROV) Stock Passes Above 200 Day Moving Average of $2.07TrovaGene (NASDAQ:TROV) Stock Passes Above 200 Day Moving Average of $2.07
www.americanbankingnews.com - July 29 at 4:30 AM
TrovaGene (NASDAQ:TROV) Stock Crosses Above 200-Day Moving Average of $1.93TrovaGene (NASDAQ:TROV) Stock Crosses Above 200-Day Moving Average of $1.93
www.americanbankingnews.com - July 21 at 3:33 AM
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AMLCardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
finance.yahoo.com - June 15 at 10:03 AM
Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose CytarabTrovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarab
www.bloomberg.com - June 14 at 11:04 PM
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCOCardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
finance.yahoo.com - May 29 at 8:44 AM
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal CancerCardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
finance.yahoo.com - May 28 at 8:55 AM
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn BioventuresCardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
finance.yahoo.com - May 27 at 12:17 PM
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer - PRNewswireCardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer - PRNewswire
www.prnewswire.com - May 19 at 8:46 AM
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive OfficerCardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
finance.yahoo.com - May 19 at 8:46 AM
BRIEF-Trovagene Announces First Quarter 2020 Results And Highlights - ReutersBRIEF-Trovagene Announces First Quarter 2020 Results And Highlights - Reuters
www.reuters.com - May 7 at 10:38 PM
Trovagene Announces First Quarter 2020 Results and Highlights - PRNewswireTrovagene Announces First Quarter 2020 Results and Highlights - PRNewswire
www.prnewswire.com - May 7 at 5:37 PM
Trovagene Announces First Quarter 2020 Results and HighlightsTrovagene Announces First Quarter 2020 Results and Highlights
finance.yahoo.com - May 7 at 5:37 PM
FDA Decision On BMYs Drug Postponed, ENTAs PBC Study Fails, MGNX Turns Heads - NasdaqFDA Decision On BMY's Drug Postponed, ENTA's PBC Study Fails, MGNX Turns Heads - Nasdaq
www.nasdaq.com - May 7 at 12:15 AM
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer - PRNewswireTrovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer - PRNewswire
www.prnewswire.com - May 6 at 12:28 PM
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive OfficerTrovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
finance.yahoo.com - May 6 at 12:28 PM
Trovagene up 48% on positive onvansertib data - Seeking AlphaTrovagene up 48% on positive onvansertib data - Seeking Alpha
seekingalpha.com - April 28 at 2:10 PM
BRIEF-Onvansertib Trial In KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across Kras Mutation Subtypes And Durable Response - ReutersBRIEF-Onvansertib Trial In KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across Kras Mutation Subtypes And Durable Response - Reuters
www.reuters.com - April 28 at 9:09 AM
Trovagene (TROV) Says Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response - StreetInsider.comTrovagene (TROV) Says Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response - StreetInsider.com
www.streetinsider.com - April 28 at 9:09 AM
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response - PRNewswireOnvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response - PRNewswire
www.prnewswire.com - April 28 at 9:09 AM
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable ResponseOnvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response
finance.yahoo.com - April 28 at 9:09 AM
BRIEF-Trovagene Expands Board With Addition Of Three Industry Leaders - ReutersBRIEF-Trovagene Expands Board With Addition Of Three Industry Leaders - Reuters
www.reuters.com - April 22 at 12:53 PM
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD - Yahoo FinanceTrovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD - Yahoo Finance
finance.yahoo.com - April 22 at 12:53 PM
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhDTrovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
finance.yahoo.com - April 22 at 12:53 PM
Form 8-K Trovagene, Inc. For: Apr 09 - StreetInsider.comForm 8-K Trovagene, Inc. For: Apr 09 - StreetInsider.com
www.streetinsider.com - April 11 at 7:11 AM
How TrovaGene, Inc. (NASDAQ:TROV) Can Impact Your Portfolio Volatility - Yahoo Finance UKHow TrovaGene, Inc. (NASDAQ:TROV) Can Impact Your Portfolio Volatility - Yahoo Finance UK
uk.finance.yahoo.com - April 9 at 7:39 PM
How TrovaGene, Inc. (NASDAQ:TROV) Can Impact Your Portfolio VolatilityHow TrovaGene, Inc. (NASDAQ:TROV) Can Impact Your Portfolio Volatility
finance.yahoo.com - April 9 at 2:39 PM
Trovagene to Present at the 19th Annual Needham Healthcare Conference - PRNewswireTrovagene to Present at the 19th Annual Needham Healthcare Conference - PRNewswire
www.prnewswire.com - April 8 at 1:50 PM
Trovagene to Present at the 19th Annual Needham Healthcare Conference - Yahoo FinanceTrovagene to Present at the 19th Annual Needham Healthcare Conference - Yahoo Finance
finance.yahoo.com - April 8 at 8:50 AM
Trovagene to Present at the 19th Annual Needham Healthcare ConferenceTrovagene to Present at the 19th Annual Needham Healthcare Conference
finance.yahoo.com - April 8 at 8:50 AM
Form 8-K Trovagene, Inc. For: Apr 01 - StreetInsider.comForm 8-K Trovagene, Inc. For: Apr 01 - StreetInsider.com
www.streetinsider.com - April 2 at 2:39 AM
Trovagene Announces Acceptance of Phase 1b/2 KRAS...Trovagene Announces Acceptance of Phase 1b/2 KRAS...
www.benzinga.com - April 1 at 9:38 PM
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting - PRNewswireTrovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting - PRNewswire
www.prnewswire.com - April 1 at 4:38 PM
BRIEF-Trovagene Offering 800,000 Shares Of Common Stock - ReutersBRIEF-Trovagene Offering 800,000 Shares Of Common Stock - Reuters
www.reuters.com - March 31 at 8:42 PM
BRIEF-Trovagene Announces Three New Nominees For Election To Board Of DirectorsBRIEF-Trovagene Announces Three New Nominees For Election To Board Of Directors
www.reuters.com - March 13 at 2:43 PM
BRIEF-Trovagene Announces Three New Nominees For Election To Board Of Directors - ReutersBRIEF-Trovagene Announces Three New Nominees For Election To Board Of Directors - Reuters
www.reuters.com - March 5 at 3:00 PM
Trovagene Announces Three New Nominees for Election to Board of Directors - Yahoo FinanceTrovagene Announces Three New Nominees for Election to Board of Directors - Yahoo Finance
finance.yahoo.com - March 5 at 9:59 AM
Trovagene Announces Three New Nominees for Election to Board of DirectorsTrovagene Announces Three New Nominees for Election to Board of Directors
finance.yahoo.com - March 5 at 9:59 AM
Trovagene Announces Fourth Quarter and Full-Year 2019 Results - PRNewswireTrovagene Announces Fourth Quarter and Full-Year 2019 Results - PRNewswire
www.prnewswire.com - February 27 at 6:34 PM
Trovagene Announces Fourth Quarter and Full-Year 2019 ResultsTrovagene Announces Fourth Quarter and Full-Year 2019 Results
finance.yahoo.com - February 27 at 6:34 PM
Trovagene (TROV) Highlights Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga-Resistance and Provide Clinical Benefit for mCRPC Patients - StreetInsider.comTrovagene (TROV) Highlights Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga-Resistance and Provide Clinical Benefit for mCRPC Patients - StreetInsider.com
www.streetinsider.com - February 13 at 10:06 PM
BRIEF-Trovagene Announces Positive Data from Phase 2 Trial Of Onvansertib In Combination With Zytiga - ReutersBRIEF-Trovagene Announces Positive Data from Phase 2 Trial Of Onvansertib In Combination With Zytiga - Reuters
www.reuters.com - February 13 at 12:05 PM
Trovagene down 10% premarket on mid-stage onvansertib data - Seeking AlphaTrovagene down 10% premarket on mid-stage onvansertib data - Seeking Alpha
seekingalpha.com - February 13 at 12:05 PM
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC PatientsTrovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
finance.yahoo.com - February 13 at 12:05 PM
ADXS, TROV On Watch, NRBO Soars 95%, DCPH To Face FDA In Aug. - NasdaqADXS, TROV On Watch, NRBO Soars 95%, DCPH To Face FDA In Aug. - Nasdaq
www.nasdaq.com - February 13 at 1:40 AM
Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium - Yahoo FinanceTrovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium - Yahoo Finance
finance.yahoo.com - February 5 at 5:09 PM
This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.